Abstract
Two articles, one by Stekler et al. in this issue of AIDS [1] and the second by Pilcher et al. in theNew England Journal of Medicine, [2] are the most recent in a series of studies applying nucleic-acid amplification testing (NAT) to diagnose pre-seroconvesion window-phase HIV-1 infections [3–8]. We review key observations from these studies, and address issues impacting expanded use of NAT in donor screening, public health surveillance and diagnostic screening settings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
